Physician profile
Cassie Seitz
NPI 1336716182
$1,951.73
in general payments reported to CMS, 2019-2025
19 companies · $402 in 2025
The $402 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $105 · 2023: $842 · 2024: $603 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,846.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $330.72 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $313.48 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $259.76 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $198.16 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.48 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $174.46 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $167.40 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $64.08 | 2023-2024 | Veozah |
| Pfizer INC. | $50.65 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $31.36 | 2025 | Zoryve |
| Inspire Medical Systems, INC. | $27.98 | 2025 | Inspire |
| Dynavax Technologies Corporation | $26.59 | 2023 | Heplisav-B |
| Merck Sharp & Dohme LLC | $24.42 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Amgen INC. | $21.21 | 2025 | Repatha |
| Ibsa Pharma INC. | $20.35 | 2025 | Flector, Licart, Tirosint |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $17.33 | 2024 | Dexcom G6 Transmitter |
| Tolmar, INC. | $16.71 | 2025 | Jatenzo |
| Antares Pharma, INC. | $16.37 | 2024 | Xyosted |
| Takeda Pharmaceuticals U.S.A., INC. | $15.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassie Seitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.